BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide fragment derived from a sequence isolated from human gastric juice. First described by researchers at the University of Zagreb in the 1990s, it belongs to the BPC-family of peptides and is classified as a research chemical with no approved therapeutic indication in any major regulatory jurisdiction as of mid-2025. It is not a growth hormone secretagogue, not a hormone itself, and does not appear to operate through classical anabolic pathways, which distinguishes it from many other peptides commonly discussed in performance and recovery contexts. This content is provided for educational purposes only and does not constitute medical advice.

The proposed mechanisms of action for BPC-157 are unusually broad for a single peptide and have been characterized primarily in in vitro and rodent studies. Research suggests it may upregulate growth hormone receptor expression in tendon fibroblasts, promote angiogenesis (new blood vessel formation) via VEGFR2 signaling, modulate nitric oxide synthesis, and interact with the dopaminergic and serotonergic systems in the central nervous system. Studies in rodent models also indicate potential cytoprotective effects on the gastrointestinal mucosa, possibly through the upregulation of early growth response protein 1 (EGR-1). The peptide does not appear to significantly alter systemic hormone levels, which may partly explain its reported tolerability in animal models. Exactly how these mechanisms translate to human physiology remains an open question.

The evidence base for BPC-157 is heavily weighted toward animal studies. Rodent trials — many conducted by the Zagreb research group led by Predrag Sikiric — have reported accelerated healing of tendons, ligaments, muscle, bone, and gut tissue across dozens of published papers. A 2018 study in the Journal of Orthopaedic Research demonstrated improved tendon-to-bone healing in a rat rotator cuff model. Separate rodent studies have examined effects on Achilles tendon transection, colitis, fistula, and traumatic brain injury. The animal evidence is voluminous but has not been independently replicated at scale by research groups outside the originating institution, which is a meaningful methodological limitation. As of mid-2025, no phase II or III human RCTs have been completed and published. One registered clinical trial (NCT04830839) was listed on ClinicalTrials.gov examining BPC-157 in inflammatory bowel disease, though its completion status should be independently verified. User-reported anecdotal evidence is extensive across forums such as Reddit's r/Peptides community, with self-reporters frequently describing faster recovery from musculoskeletal injuries, reduced joint pain, and improved gut symptoms — though anecdotal reports cannot establish causation and are subject to significant placebo bias and survivorship effects.

Dosing ranges reported in published animal research contexts typically fall between 1–10 mcg/kg of body weight administered intraperitoneally or subcutaneously in rodent models. Community-reported human self-experimentation dosing frequently cited in forums ranges from approximately 200–500 mcg per day administered via subcutaneous injection or intramuscular injection, sometimes with oral or sublingual administration discussed for gastrointestinal applications specifically. These ranges are reported here strictly as observed in research and community literature — they do not constitute a dosing recommendation, and no safe or effective human dose has been established through clinical trials. Reconstitution with bacteriostatic water is required for lyophilized powder formulations.

In terms of legal status and sourcing, BPC-157 is classified as a research chemical and is not approved for human consumption by the FDA (United States), MHRA (United Kingdom), EMA (European Union), or TGA (Australia). It is not a controlled or scheduled substance in most jurisdictions, but selling or purchasing it for human use is legally ambiguous at best. Vendors operating in the research-chemical space vary significantly in quality. A credible supplier will provide a certificate of analysis (COA) from an independent third-party laboratory confirming peptide identity, purity (typically ≥98% by HPLC), and absence of common contaminants. Vendors who cannot supply COAs, who sell pre-reconstituted solutions, or who make explicit therapeutic claims on their websites are red flags. Purity and accurate dosing of research-chemical peptides are not guaranteed by any regulatory body, and the gap between labeled and actual content can be substantial in low-quality supply chains.